Phase 1 Open-Label Dose Escalation and Expansion Study of SNV1521 in Patients with Advanced Solid Tumors

The primary objective of this study is to evaluate the safety and tolerability of **SNV1521** in participants with **advanced solid tumors**. This is clinically relevant as it aims to determine the maximum tolerated dose and identify any dose-limiting toxicities, which are critical for establishing a safe dosage regimen for future clinical trials. The study does not specify any secondary objectives.

The clinical trial involves a total of **200 participants** diagnosed with **Advanced Solid Tumors**. The study population includes both male and female subjects, with an age range spanning from young adults to older adults. Participants were selected without targeting any vulnerable populations. The general health status of the participants is not specified, but they are likely to be in a condition that allows for trial participation given the nature of the disease. Lifestyle considerations such as diet, physical activity, or habits are not detailed in the available data. The sponsor has not provided specific information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed as a **Phase 1** open-label, dose escalation and expansion study, focusing on participants with **advanced solid tumors**. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of the investigational product SNV1521. The study is scheduled to commence recruitment on May 1, 2025, with an estimated completion date of February 2, 2027. The trial will involve a series of structured visits, beginning with an inclusion visit, where participants will undergo screening to confirm eligibility based on predefined criteria. This initial visit will include assessments such as medical history review, physical examination, and laboratory tests to ensure participants meet the study's inclusion criteria.

Following the inclusion visit, participants will enter the dose escalation phase, where they will receive increasing doses of SNV1521 to determine the maximum tolerated dose. Regular follow-up visits will be conducted to monitor participants' safety and response to the treatment. These visits will include clinical evaluations, laboratory tests, and imaging studies as necessary. The frequency and duration of follow-up visits will be determined by the study protocol and the specific needs of each participant. The end-of-study visit will mark the conclusion of the participant's involvement in the trial, during which final assessments will be conducted to evaluate the overall outcomes and any long-term effects of the treatment.

Participant involvement is expected to last until the end-of-study visit, unless early termination is warranted. Conditions that may lead to early termination include adverse events, withdrawal of consent, or any other circumstances that compromise participant safety or data integrity. The trial's design and procedures are structured to ensure rigorous data collection and analysis, contributing to the understanding of SNV1521's potential therapeutic benefits for individuals with advanced solid tumors.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is May 1, 2025, with an anticipated end date of February 2, 2027. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. The trial will likely employ standardized methods for measuring and collecting data, which may include validated scales, laboratory tests, or patient-reported outcomes, depending on the investigational product and the condition being studied. The analysis of efficacy data will be conducted in accordance with the trial's protocol, ensuring rigorous and scientifically sound conclusions. The absence of detailed endpoints suggests that the primary focus may be on safety and tolerability, with efficacy assessments being exploratory in nature.